About M8 Pharmaceuticals
M8 Pharmaceuticals is a Healthcare company based in Berwyn (United States) founded in 2007, and was acquired by Acino in December 2023. Pharmaceutical company develop and commercialize leading original medicines. M8 Pharmaceuticals has raised $264.41 million across 9 funding rounds from investors including Teva Pharmaceuticals, TPG and Knight Therapeutics. Its chief executive, as recorded, is Joel Barlan. M8 Pharmaceuticals offers products and services including Innovative Medicines and Partnership Services. Its focus areas include Traditional Pharmaceuticals. Its legal entity is M8 Pharmaceuticals, Inc.
Company details
M8 Pharmaceuticals was founded in 2007 and is headquartered in Berwyn, United States. Operations in the pharmaceutical sector involve partnerships with other companies to develop and commercialize original medicines. Access to established treatments is facilitated for patients across Latin America, with a focus on regional distribution and market entry strategies. Leadership is provided by CEO Joel Barlan.
- Headquarters Berwyn, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website m8pharmaceuticals.com
- Social LinkedIn
- Acquired by Acino (Dec 2023)
- Legal Name M8 Pharmaceuticals, Inc
- Total Equity Funding$264.41M (USD)
in 9 rounds
- Latest Funding Round$25M (USD), Debt – Conventional
Feb 2019
- InvestorsTeva Pharmaceuticals
& 4 more
- Acquired byAcino
(Dec 2023)
Products & Services of M8 Pharmaceuticals
M8 Pharmaceuticals offers a comprehensive portfolio of products and services, including Innovative Medicines and Partnership Services.
Innovative medicines are developed and commercialized in therapeutic areas like Central Nervous System and Oncology
Strategic partnerships are formed for licensing and commercialization of medicines in global markets
Funding Insights of M8 Pharmaceuticals
M8 Pharmaceuticals has successfully raised a total of $264.41M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $264.41M
- Total Rounds 9
- Last Round Debt – Conventional — $25M
- First Round $24M
(Jan 2008)
- Investors Count 4
All 9 funding rounds of M8 Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2019 | $25M | Debt – Conventional | – | – | |
| Oct 2012 | $125M | Series E | – | Forest Laboratories | – |
| Oct 2010 | $60.97M | Series D | – | Teva Pharmaceuticals | – |
| Jun 2010 | $2.5M | Series C | – | – | – |
| Dec 2009 | $25.07M | Series C | – | – | – |
| Nov 2009 | $5M | Series B | – | – | – |
| Mar 2009 | $6.86M | Series B | – | – | – |
| Feb 2008 | $15M | Series B | – | – | – |
| Jan 2008 | $24M | Series A | – | TPG | – |
5 investors in total: 5 institutional.
Investors in M8 Pharmaceuticals
M8 Pharmaceuticals has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Teva Pharmaceuticals, TPG and Knight Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Fund of funds focused on pre-seed and seed-stage companies | 1992 | tpg.com | Fort Worth, United States | |
Prescription pharmaceuticals are acquired, licensed, and commercialized by the company. | 2014 | gud-knight.com | Westmount, Canada | |
Pharmaceutical formulations are developed and marketed by Forest Laboratories. | 1954 | frx.com | New York, United States | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel | |
Generic drugs are manufactured by Acino in Switzerland. | 1836 | acino.swiss | Zurich, Switzerland |
Investor details for M8 Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of M8 Pharmaceuticals
1 people are tracked at M8 Pharmaceuticals (1 in leadership).
| Name | Role | Group |
|---|---|---|
Joel Barlan | CEO | Leadership |
Complete people profiles for M8 Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of M8 Pharmaceuticals
4 dated milestones of M8 Pharmaceuticals across 16 years, from founding to its latest funding, stage changes and deals.
- Founded M8 Pharmaceuticals is founded.
- Funding First funding round of $24.0M.
- Funding Latest funding round, Debt – Conventional, of $25.0M.
- Exit Acquired by Acino.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as M8 Pharmaceuticals (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about M8 Pharmaceuticals
M8 Pharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
M8 Pharmaceuticals is headquartered in Berwyn, United States. It is registered at Berwyn, Illinois, United States.
Joel Barlan is the CEO of M8 Pharmaceuticals, as recorded in our data.
M8 Pharmaceuticals is a funded company, having raised a total of $264.41M across 9 funding rounds to date. The company's 1st funding round was a Series A of $24M, raised on Jan 2008.
M8 Pharmaceuticals was founded in 2007 and is headquartered in Berwyn, United States. Operations in the pharmaceutical sector involve partnerships with other companies to develop and commercialize original medicines. Access to established treatments is facilitated for patients across Latin America, with a focus on regional distribution and market entry strategies. Leadership is provided by CEO Joel Barlan.
M8 Pharmaceuticals offers Innovative Medicines and Partnership Services.
M8 Pharmaceuticals has 5 investors. Key investors include Teva Pharmaceuticals, TPG, Knight Therapeutics, Forest Laboratories, and Acino.
M8 Pharmaceuticals operates through M8 Pharmaceuticals, Inc.
Yes. M8 Pharmaceuticals was acquired by Acino in December 2023.